In Depth 29 Nov 2016
The ABCs of ADCs: A Review of Antibody Drug Conjugates
Antibody therapies have a little sister who is catching up in funding – and hype? In light of now five deaths from Juno’s CAR-T therapy, antibody drug conjugates are attracting a lot of interest in a resurgence after their debut 10 years ago. To feel out the field, we talked to two CEOs competing directly […]
